NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and select members of senior management, will participate in three healthcare conferences, as follows:
TD Cowen 45th Annual Health Care Conference, Boston
Monday, March 3, 2025, at 1:10pm ET
Join the webcast
Leerink Partners Global Healthcare Conference, Miami
Wednesday, March 12, 2025 (1x1 meetings)
BIO-Europe Spring, Milan
March 17-19, 2025
The live and archived webcasts will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 90 days.
About Bright Minds Biosciences
Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.
Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Contact Information
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: www.brightmindsbio.com
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$71.00 |
| Daily Change: | 4.84 7.32 |
| Daily Volume: | 64,959 |
| Market Cap: | US$503.390M |
November 25, 2025 November 06, 2025 October 30, 2025 September 04, 2025 September 04, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
